Key facts, as of
As of October 8, 2026, Regeneron Pharmaceuticals (REGN) trades at $742.12, up 27.2% over the past year. Its 52-week range runs from $541.00 to $859.34; the price is 13.6% below that high. It is 38.7% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +90.4%, against +312.9% for the S&P 500 (SPY). It sits 0.9% above its 200-day average of $735.86, the usual sign of a long-term uptrend. Its 30-day volatility is 25.8% annualized, which we rate medium risk. It has a trailing P/E of 18.4 and a dividend yield of 0.51%.
Cite: Portfolio Terminal, "Regeneron Pharmaceuticals (REGN) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/regn
Where it trades today
trading 63% of the way up its 52-week range
How the price has moved
How far it is from its record
Regeneron Pharmaceuticals (REGN) is 38.7% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +90.4%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- REGN trades at 18.4x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- REGN carries a beta of 0.15, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- REGN remains in a bearish short-term trend and sits 13.6% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- REGN is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for REGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for REGN. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent…
What analysts expect
REGN carries a buy consensus from 26 analysts, with an average price target of $856.23 versus $742.12 today (+15.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
REGN generated $15.53B in trailing revenue (16.7% year over year), with a 27.9% net margin, and $3.07B of free cash flow, supported by $5.29B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $14.34B | $12.24B | $3.70B | $4.50B | $43.07 | $3.77B |
| 2024 | $14.20B | $12.23B | $3.99B | $4.41B | $40.90 | $3.54B |
| 2023 | $13.12B | $11.30B | $4.05B | $3.95B | $37.05 | $3.67B |
| 2022 | $12.17B | $10.61B | $4.74B | $4.34B | $40.51 | $3.40B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
REGN is in 9 of the 30 ETFs we track. It weighs most in XLV: 1.26% of the fund, holding #20 of 62.
Famous investors who hold it
REGN is in the latest 13F of 2 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.13% of the portfolio, position #124 of 992, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
REGN beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 5.9% below its 50-day average and 0.9% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-03 (a “golden cross”).
- RSI at 40 is neither stretched nor washed out.
- The nearest ceiling is $750.69 (+1.2%), the nearest floor $729.14 (-1.7%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is REGN a good investment in 2026?
Regeneron Pharmaceuticals trades at a P/E ratio of 18.4, with medium volatility (25.8% annualized). Recent trend shows weakness.
What is the risk level of REGN?
Based on 30-day volatility of 25.8%, REGN has MEDIUM risk. Beta of 0.15 indicates lower sensitivity to market movements than average.
Does REGN pay dividends?
Yes, Regeneron Pharmaceuticals has a dividend yield of 0.51%.
How far is REGN from its all-time high?
Regeneron Pharmaceuticals is 38.7% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +90.4%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold REGN?
9 of the 30 popular ETFs we track hold Regeneron Pharmaceuticals. The largest weights: XLV (1.26%), JEPI (1.05%), QQQ (0.34%), QQQM (0.31%) and VTV (0.30%). Measured on each issuer's full holdings file, dated August 31 to October 1, 2026.
How much of VOO is REGN?
0.12%, as of August 31, 2026: REGN is holding #147 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.21 in Regeneron Pharmaceuticals.
Which famous investors own REGN?
Ray Dalio (0.13% of Bridgewater Associates's 13F) and Renaissance Technologies (0.13% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for REGN?
The average analyst price target for Regeneron Pharmaceuticals (REGN) is $856.23 based on 26 analyst estimates, about 15.4% above the current price of $742.12. The published range runs from $730.00 to $1030.00.
How much revenue does REGN generate?
Regeneron Pharmaceuticals reported $15.53B in trailing twelve-month revenue. Revenue growth is running at 16.7% year over year. Net margin sits at 27.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare REGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.